Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target

Johnson & Johnson (NYSE:JNJ) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In.

Following a strong positive quarter, the company witnesses a rise in price target and announces new data on its pill.

Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target

Johnson & Johnson (NYSE: JNJ) reported an EPS of $2.77 for the second quarter of 2025 on July 16, 2025, successfully surpassing the consensus analyst estimate of $2.68. Similarly, the company’s revenue of $23.74 billion for the quarter exceeded analyst expectations of $22.85 billion, signaling a good performance amid a complex economic environment. The company’s board has also declared a quarterly cash dividend of $1.30 per share, representing a 63rd consecutive annual dividend increase and a growth from the previous quarter’s rate of $1.24 per share.

Following the strong quarter, JP Morgan raised the stock’s price target from $185 to $195 while keeping a Neutral rating. Additionally, the company announced new data from the Phase 3 Iconic-Advance 1 and 2 studies on icotrokinra, which hints at the superiority of the pill to deucravacitinib and placebo in treating moderate-to-severe plaque psoriasis.

Holding on to this positive outlook, Johnson & Johnson (NYSE:JNJ) offers a dividend yield of 2.95% attracting investors looking for a stable income.

The American multinational corporation, Johnson & Johnson (NYSE:JNJ), was founded in 1886. Headquartered in New Jersey, the company is a global leader in the healthcare industry, specializing in the development of pharmaceuticals and consumer health products.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Performing IPOs in the Last 2 Years and 12 Jim Cramer Stock Picks this Week

Disclosure. None.